Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03259074




Registration number
NCT03259074
Ethics application status
Date submitted
21/08/2017
Date registered
23/08/2017
Date last updated
21/08/2023

Titles & IDs
Public title
Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
Scientific title
A Randomized, Partially-blinded Study of Secukinumab to Demonstrate Reduction of Radiographic Progression Versus GP2017 (Adalimumab Biosimilar) at 104 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis
Secondary ID [1] 0 0
CAIN457K2340
Universal Trial Number (UTN)
Trial acronym
SURPASS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ankylosing Spondylitis 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Placebo
Treatment: Other - GP2017 (adalimumab biosimilar)
Treatment: Other - AIN457 150 mg

Experimental: AIN457 150 mg/placebo - AIN457 150 mg and a matching placebo was administered subcutaneously via pre-filled syringes at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 100

Experimental: AIN457 300 mg - AIN457 300 mg (2 x 150 mg) was administered subcutaneously via pre-filled syringes at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 100

Active comparator: GP2017 40mg - GP2017 (adalimumab biosimilar) 40 mg was administered subcutaneously via pre-filled syringes at Baseline followed by dosing every 2 weeks until Week 102


Treatment: Other: Placebo
Matching placebo to AIN457 150 mg dose administered with AIN457 via pre-filled syringes

Treatment: Other: GP2017 (adalimumab biosimilar)
40 mg in pre-filled syringes was administered subcutaneously

Treatment: Other: AIN457 150 mg
150 mg in pre-filled syringes was administered subcutaneously
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With no Radiographic Progression at Week 104 (Multiple Imputation) (Full Analysis Set)
Timepoint [1] 0 0
Baseline and at Week 104
Secondary outcome [1] 0 0
Change From Baseline in mSASSS at Week 104 (Multiple Imputation) (Full Analysis Set)
Timepoint [1] 0 0
Baseline and at Week 104
Secondary outcome [2] 0 0
Percentage of Participants Without New Syndesmophytes by mSASSS Between Baseline and Week 104 (Multiple Imputation) (Syndesmophyte Subset)
Timepoint [2] 0 0
Baseline and at Week 104
Secondary outcome [3] 0 0
Change From Baseline in MRI Berlin Sacroiliac (SI) Joint Edema Score (Observed Data) (MRI Subset)
Timepoint [3] 0 0
Baseline and at Week 104
Secondary outcome [4] 0 0
Change From Baseline in Berlin Modification of ASspiMRI-a Edema Score (MRI Subset)
Timepoint [4] 0 0
Baseline and at Week 104
Secondary outcome [5] 0 0
Percentage of Responders for Assessment of SpondyloArthritis International Society 20 (ASAS20)
Timepoint [5] 0 0
Week 104
Secondary outcome [6] 0 0
Percentage of Responders for Assessment of SpondyloArthritis International Society 40 (ASAS 40)
Timepoint [6] 0 0
Week 104
Secondary outcome [7] 0 0
Percentage of Responders for Assessment of SpondyloArthritis International Society With a Partial Remission Response (Full Analysis Set)
Timepoint [7] 0 0
Week 104
Secondary outcome [8] 0 0
Percentage of Participants With Assessment of SpondyloArthritis International Society for Inactive Disease Response (Observed Data) (Full Analysis Set)
Timepoint [8] 0 0
Week 104

Eligibility
Key inclusion criteria
* Male or non-pregnant, non-nursing female patients at least 18 years of age
* Diagnosis of moderate to severe Ankylosing Spondylitis with radiologic evidence (centrally read X-ray) fulfilling the Modified New York criteria for AS despite previous or current NSAID/ nonbiologic DMARD therapy
* Active AS assessed by total BASDAI = 4 on a scale of 0-10
* Spinal pain as measured by BASDAI question #2 = 4 (0-10)
* Total back pain as measured by visual analog scale (VAS) = 40 mm (0-100 mm)
* hsCRP = 5 mg/L OR presence of at least 1 syndesmophyte on centrally read spinal X-ray
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Patients with total ankylosis of the spine
* Pregnant or nursing (lactating) women
* Evidence of ongoing infectious or malignant process
* Previous exposure to any biologic immunomodulating agent, including those targeting IL-17, IL-17 receptor or TNFa
* Subjects taking high potency opioid analgesics
* Previous treatment with any cell-depleting therapies including but not limited to anti-CD20, investigational agents

Other protocol-defined inclusion/exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/11/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
29/11/2021
Sample size
Target
Accrual to date
Final
859
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Malvern East
Recruitment postcode(s) [1] 0 0
3145 - Malvern East
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Idaho
Country [5] 0 0
United States of America
State/province [5] 0 0
Louisiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Montana
Country [8] 0 0
United States of America
State/province [8] 0 0
Nebraska
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Oregon
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
Tennessee
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Washington
Country [16] 0 0
United States of America
State/province [16] 0 0
Wisconsin
Country [17] 0 0
Argentina
State/province [17] 0 0
Ciudad Autonoma de Bs As
Country [18] 0 0
Belgium
State/province [18] 0 0
Bruxelles
Country [19] 0 0
Belgium
State/province [19] 0 0
Genk
Country [20] 0 0
Canada
State/province [20] 0 0
Manitoba
Country [21] 0 0
Canada
State/province [21] 0 0
Ontario
Country [22] 0 0
Canada
State/province [22] 0 0
Quebec
Country [23] 0 0
Chile
State/province [23] 0 0
RM
Country [24] 0 0
Chile
State/province [24] 0 0
Concepcion
Country [25] 0 0
Chile
State/province [25] 0 0
Santiago
Country [26] 0 0
Colombia
State/province [26] 0 0
Santander
Country [27] 0 0
Colombia
State/province [27] 0 0
Barranquilla
Country [28] 0 0
Czechia
State/province [28] 0 0
CZE
Country [29] 0 0
Czechia
State/province [29] 0 0
Brno
Country [30] 0 0
Czechia
State/province [30] 0 0
Praha 11
Country [31] 0 0
Czechia
State/province [31] 0 0
Praha 2
Country [32] 0 0
Czechia
State/province [32] 0 0
Uherske Hradiste
Country [33] 0 0
Denmark
State/province [33] 0 0
Aalborg
Country [34] 0 0
Denmark
State/province [34] 0 0
Copenhagen
Country [35] 0 0
Finland
State/province [35] 0 0
Joensuu
Country [36] 0 0
France
State/province [36] 0 0
Cedex1
Country [37] 0 0
France
State/province [37] 0 0
Boulogne Billancourt
Country [38] 0 0
France
State/province [38] 0 0
Le Mans
Country [39] 0 0
France
State/province [39] 0 0
Monaco
Country [40] 0 0
France
State/province [40] 0 0
Paris Cedex 14
Country [41] 0 0
France
State/province [41] 0 0
Paris
Country [42] 0 0
France
State/province [42] 0 0
Toulouse
Country [43] 0 0
Germany
State/province [43] 0 0
Bad Doberan
Country [44] 0 0
Germany
State/province [44] 0 0
Bayreuth
Country [45] 0 0
Germany
State/province [45] 0 0
Berlin
Country [46] 0 0
Germany
State/province [46] 0 0
Chemnitz
Country [47] 0 0
Germany
State/province [47] 0 0
Erlangen
Country [48] 0 0
Germany
State/province [48] 0 0
Gottingen
Country [49] 0 0
Germany
State/province [49] 0 0
Hamburg
Country [50] 0 0
Germany
State/province [50] 0 0
Herne
Country [51] 0 0
Germany
State/province [51] 0 0
Magdeburg
Country [52] 0 0
Germany
State/province [52] 0 0
Planegg
Country [53] 0 0
Germany
State/province [53] 0 0
Ratingen
Country [54] 0 0
Greece
State/province [54] 0 0
GR
Country [55] 0 0
Greece
State/province [55] 0 0
Athens
Country [56] 0 0
Israel
State/province [56] 0 0
Haifa
Country [57] 0 0
Israel
State/province [57] 0 0
Tel Aviv
Country [58] 0 0
Japan
State/province [58] 0 0
Hyogo
Country [59] 0 0
Japan
State/province [59] 0 0
Kagawa
Country [60] 0 0
Japan
State/province [60] 0 0
Kochi
Country [61] 0 0
Japan
State/province [61] 0 0
Nara
Country [62] 0 0
Japan
State/province [62] 0 0
Tokyo
Country [63] 0 0
Korea, Republic of
State/province [63] 0 0
Seocho Gu
Country [64] 0 0
Korea, Republic of
State/province [64] 0 0
Gwangju
Country [65] 0 0
Korea, Republic of
State/province [65] 0 0
Seoul
Country [66] 0 0
Mexico
State/province [66] 0 0
Baja California
Country [67] 0 0
Mexico
State/province [67] 0 0
Coahulia
Country [68] 0 0
Mexico
State/province [68] 0 0
MEX
Country [69] 0 0
Mexico
State/province [69] 0 0
Nuevo Leon
Country [70] 0 0
Mexico
State/province [70] 0 0
San Luis potosi
Country [71] 0 0
Netherlands
State/province [71] 0 0
Zuid-Holland
Country [72] 0 0
Netherlands
State/province [72] 0 0
Amsterdam
Country [73] 0 0
Netherlands
State/province [73] 0 0
Leeuwarden
Country [74] 0 0
Netherlands
State/province [74] 0 0
Maastricht
Country [75] 0 0
Netherlands
State/province [75] 0 0
Rotterdam
Country [76] 0 0
Peru
State/province [76] 0 0
Lima
Country [77] 0 0
Philippines
State/province [77] 0 0
Manila
Country [78] 0 0
Philippines
State/province [78] 0 0
Quezon City
Country [79] 0 0
Poland
State/province [79] 0 0
Bydgoszcz
Country [80] 0 0
Poland
State/province [80] 0 0
Dopiewo
Country [81] 0 0
Poland
State/province [81] 0 0
Krakow
Country [82] 0 0
Poland
State/province [82] 0 0
Poznan
Country [83] 0 0
Poland
State/province [83] 0 0
Sopot
Country [84] 0 0
Portugal
State/province [84] 0 0
Almada
Country [85] 0 0
Portugal
State/province [85] 0 0
Lisboa
Country [86] 0 0
Portugal
State/province [86] 0 0
Ponte de Lima
Country [87] 0 0
Portugal
State/province [87] 0 0
Porto
Country [88] 0 0
Portugal
State/province [88] 0 0
Vila Nova de Gaia
Country [89] 0 0
Romania
State/province [89] 0 0
Bucharest
Country [90] 0 0
Romania
State/province [90] 0 0
Bucuresti
Country [91] 0 0
Romania
State/province [91] 0 0
Cluj Napoca
Country [92] 0 0
Russian Federation
State/province [92] 0 0
Barnaul
Country [93] 0 0
Russian Federation
State/province [93] 0 0
Chelyabinsk
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Ekaterinburg
Country [95] 0 0
Russian Federation
State/province [95] 0 0
Ivanovo
Country [96] 0 0
Russian Federation
State/province [96] 0 0
Kazan
Country [97] 0 0
Russian Federation
State/province [97] 0 0
Kemerovo
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Moscow
Country [99] 0 0
Russian Federation
State/province [99] 0 0
Petrozavodsk
Country [100] 0 0
Russian Federation
State/province [100] 0 0
Saint Petersburg
Country [101] 0 0
Russian Federation
State/province [101] 0 0
St Petersburg
Country [102] 0 0
Russian Federation
State/province [102] 0 0
Ufa
Country [103] 0 0
Russian Federation
State/province [103] 0 0
Yaroslavl
Country [104] 0 0
Slovakia
State/province [104] 0 0
Slovak Republic
Country [105] 0 0
Slovakia
State/province [105] 0 0
SVK
Country [106] 0 0
Slovakia
State/province [106] 0 0
Bratislava
Country [107] 0 0
Slovakia
State/province [107] 0 0
Kosice
Country [108] 0 0
Slovakia
State/province [108] 0 0
Stara Lubovna
Country [109] 0 0
Spain
State/province [109] 0 0
Alicante
Country [110] 0 0
Spain
State/province [110] 0 0
Bizkaia
Country [111] 0 0
Spain
State/province [111] 0 0
Cantabria
Country [112] 0 0
Spain
State/province [112] 0 0
Catalunya
Country [113] 0 0
Spain
State/province [113] 0 0
Galicia
Country [114] 0 0
Spain
State/province [114] 0 0
Pais Vasco
Country [115] 0 0
Spain
State/province [115] 0 0
Pontevedra
Country [116] 0 0
Spain
State/province [116] 0 0
Vitoria Gasteiz
Country [117] 0 0
Spain
State/province [117] 0 0
Madrid
Country [118] 0 0
Spain
State/province [118] 0 0
Valencia
Country [119] 0 0
Taiwan
State/province [119] 0 0
Taiwan ROC
Country [120] 0 0
Taiwan
State/province [120] 0 0
Dalin
Country [121] 0 0
Taiwan
State/province [121] 0 0
Kaohsiung
Country [122] 0 0
Taiwan
State/province [122] 0 0
Taipei
Country [123] 0 0
Turkey
State/province [123] 0 0
TUR
Country [124] 0 0
Turkey
State/province [124] 0 0
Ankara
Country [125] 0 0
Turkey
State/province [125] 0 0
Eskisehir
Country [126] 0 0
Turkey
State/province [126] 0 0
Izmir
Country [127] 0 0
Turkey
State/province [127] 0 0
Kocaeli
Country [128] 0 0
United Kingdom
State/province [128] 0 0
Dorset
Country [129] 0 0
United Kingdom
State/province [129] 0 0
Edmonton
Country [130] 0 0
United Kingdom
State/province [130] 0 0
GBR
Country [131] 0 0
United Kingdom
State/province [131] 0 0
Hants
Country [132] 0 0
United Kingdom
State/province [132] 0 0
London
Country [133] 0 0
United Kingdom
State/province [133] 0 0
Staffordshire
Country [134] 0 0
United Kingdom
State/province [134] 0 0
Bath
Country [135] 0 0
United Kingdom
State/province [135] 0 0
Bristol
Country [136] 0 0
United Kingdom
State/province [136] 0 0
Leicester
Country [137] 0 0
United Kingdom
State/province [137] 0 0
Liverpool
Country [138] 0 0
United Kingdom
State/province [138] 0 0
Norwich
Country [139] 0 0
United Kingdom
State/province [139] 0 0
Torquay
Country [140] 0 0
United Kingdom
State/province [140] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to demonstrate the impact of secukinumab on the progression of structural damage in the spine, as measured by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) in patients with Ankylosing Spondylitis (AS).
Trial website
https://clinicaltrials.gov/study/NCT03259074
Trial related presentations / publications
Sieper J, Poddubnyy D. Twenty years of clinical trials in axial spondyloarthritis: what can we learn for the future? Curr Opin Rheumatol. 2021 Jul 1;33(4):363-369. doi: 10.1097/BOR.0000000000000804.
Baraliakos X, Ostergaard M, Gensler LS, Poddubnyy D, Lee EY, Kiltz U, Martin R, Sawata H, Readie A, Porter B; SURPASS Study Group. Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS). Clin Drug Investig. 2020 Mar;40(3):269-278. doi: 10.1007/s40261-020-00886-7.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03259074